← The record

Glecaprevir With PibrentasvirMaviret

Recommended HepatologyRestrictedFirst-line line 💬 consumer voice

Treatment of chronic hepatitis C (CHC) infection in patients who are treatment-naïve with compensated cirrhosis, genotypes 1-6, with a shortened 8-week treatment duration.

3
Submissions
2 resub
2017–20
On the record
ICER range
Cost-min
Cost basis

Decision on record

1 decision
  • Meeting Nov 2017 Recommended Chronic hepatitis C virus (HCV) infection

Access path

3 submissions · public record
  1. TGA registered · Maviret

    TGA label narrower than the PBS population

  2. Jul 2017
    Deferred

    vs sofosbuvir/velpatasvir

  3. Nov 2017
    Recommended · restricted

    Comparator changed: sofosbuvir/velpatasvir → no treatment (for NS5A experienced…

  4. Dec 2020
    Recommended

    Comparator changed: no treatment (for NS5A experienced patients); sofosbuvir/velpatasvir…

  5. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
6.1 The PBAC was of a mind to recommend the listing of an 8-week treatment option of glecaprevir with pibrentasvir (GLE/PIB) for the treatment of chronic hepatitis C (CHC) infection in patients who are treatment-naïve with compensated cirrhosis (TN/CC), however deferred making a recommendation to amend the General Statement for Drugs for the Treatment of Hepatitis C (the General Statement) pending finalisation of 7PSD · Dec 2020
6.2 The PBAC was of a mind to retain the 12-week regimen option if it remains part of the TGA registration. The Committee advised that this regimen should be included as a footnote to the General Statement for simplicity and reaffirmed that any change to treatment options within the General Statement that achieve the same health outcomes must be at no increase in the average cost to the Government.PSD · Dec 2020
Economic analysis
5.14 The minor submission requested the same cost for the 8-week course as the current cost of the 12-week course by application of the existing Special Pricing Arrangement (SPA), and no changes to the risk sharing arrangements.PSD · Dec 2020
Clinical claim
5.11 The submission claimed non-inferior comparative effectiveness and safety of GLE/PIB for the 8-week treatment course compared to the 12-week course.PSD · Dec 2020
5.12 The PBAC considered that the claim of non-inferior comparative effectiveness was reasonable.PSD · Dec 2020
Consumer comments
6.2 The PBAC noted and welcomed the input received from professional organisations representing people living with hepatitis (4) via the consumer comments facility on the PBS website. The comments described a range of benefits of treatment with glecaprevir/pibrentasvir including the addition of another pan-genotypic treatment choice for patients with HCV; and that it appears to be efficacious for people with severe chronic kidney disease and compensated …PSD · Nov 2017
Financial management – risk sharing
6.46 The PBAC recommended that glecaprevir/pibrentasvir enter the Risk Sharing Arrangement (RSA) currently in place for other drugs used for the treatment of CHC, and be subject to the same subsidisation caps and rebate arrangements.PSD · Jul 2017

Cost-effectiveness

This was a minor submission requesting amendment of treatment duration; no economic evaluation with ICER was required. The submission was based on cost minimisation principles with no change to cost per treatment course.

The submission was based on a cost-minimisation analysis of glecaprevir/pibrentasvir in comparison with a FDC of sofosbuvir and velpatasvir. PSD · 2017
ICER uncertainCost-effectiveness accepted ×2

Decision context

PopulationAdults with chronic hepatitis C genotypes 1-6 who are treatment-naïve with compensated cirrhosis

Submission history

3 entries
DecidedOutcomeComparatorICEREvidence
Dec 2020 Recommended 12-week treatment course of glecaprevir with pibrentasvir (current PBS listed regimen); alternative pan-genotypic treatm Single-arm · SVR12
Nov 2017 Recommended · restricted no treatment (for NS5A experienced patients); sofosbuvir/velpatasvir (for non-NS5A experienced patients) RCT · SVR12
Jul 2017 Deferred sofosbuvir/velpatasvir Single-arm · SVR

Clinical evidence

Trials cited in the PSDs · ClinicalTrials.gov
TrialPhaseNPrimary outcomeStatus
ENDURANCE-1 Ph 3 703 Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR1… completed
ENDURANCE-3 Ph 3 506 Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR1… completed
EXPEDITION-1 Ph 3 146 Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR1… completed
EXPEDITION-4 Ph 3 104 Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR1… completed

Consumer voice

Nov 2017

Professional organisations representing people living with hepatitis provided input highlighting the benefits of glecaprevir/pibrentasvir as another pan-genotypic treatment option, particularly for patients with severe chronic kidney disease, compensated cirrhosis, and those with prior antiviral treatment experience.

the addition of another pan-genotypic treatment choice for patients with HCV Consumer comments · PSD
treatment optionsunmet needefficacy in special populationsprior treatment failure

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to treatment-naïve patients with compensated cirrhosis; TGA label includes treatment-experienced and non-cirrhotic patients.